PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.

Zhang D, Jiang L, Yu F, Yan P, Liu Y, Wu Y, Yang X

Frontiers in pharmacology15 Aug 2024Cited by 4 (Europe PMC)

PMID39211778PMCIDPMC11357942DOI10.3389/fphar.2024.1442876PepBankPUB-39211778

Summary

IntroductionInflammatory bowel disease (IBD), as a chronic and recurrent inflammatory bowel diseases with limited therapeutic outcomes, is characterized by immune disorders and intestinal barrier dysfunction. Currently, the most medications used to cure IBD in clinic just temporarily induce and maintain remission with poor response rates and limited outcomes. Therefore, it is urgently necessary to develop an appropriate therapeutic candidate with preferable efficacy and less adverse reaction for curing IBD.MethodsFive groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs). The effect of NP on the inflammatory factors of macrophage was evaluated using CCK-8, quantitative polymerase chain reaction (PCR), Elisa and Western blot (WB). Immunofluorescent staining revealed the targeting relationship between NP and Petp-1. Immunohistochemistry staining showed the effect of NP on tight junction proteins. Moreover, in vivo animal experiments confirmed that NPs reduced inflammatory levels in IBD.Results and discussionAfter administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively. Furthermore, treating by NPs revealed a notable reduction of the expressions of CD68 and CD3, restoring the expression levels of tight junction proteins (Claudin-5, Occludin-1, and ZO-1) were significantly restored, surpassing those observed in the KPV and FK506 groups. which indicated that NPs can reduce inflammation and enhance epithelial barrier integrity by decreasing the infiltration of macrophages and T-lymphocytes. Collectively, those results demonstrated the effectively therapeutic outcome after using NPs in both acute and chronic colitis, suggesting that the newly co-assembled of NPs can be as a potential therapeutic candidate for colitis.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking KPV.

01AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced acute or chronic colitis, peptide-FK506 nanoparticles (NPs) significantly improved body weight.
In plain wordsIn mice with colitis, nanoparticles of a peptide and FK506 improved body weight.
Peptide
KPV
Outcome
IncreaseBody weight
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Body weight · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177801
02AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced acute or chronic colitis, NPs significantly improved colon length.
In plain wordsIn mice with colitis, the nanoparticles improved colon length.
Peptide
KPV
Outcome
IncreaseColon length
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177802
03AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced acute or chronic colitis, NPs significantly improved the disease activity index.
In plain wordsIn mice with colitis, the nanoparticles improved the disease score.
Peptide
KPV
Outcome
DecreaseDisease activity index
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177803
04AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs decreased the oxidative stress factor MPO.
In plain wordsIn mice with colitis, the nanoparticles lowered the stress marker MPO.
Peptide
KPV
Outcome
DecreaseMyeloperoxidase level
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177804
05AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs decreased the oxidative stress factor NO.
In plain wordsIn mice with colitis, the nanoparticles lowered the stress marker nitric oxide.
Peptide
KPV
Outcome
DecreaseNitric oxide level
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177805
06AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs decreased the oxidative stress factor ROS.
In plain wordsIn mice with colitis, the nanoparticles lowered reactive oxygen species.
Peptide
KPV
Outcome
DecreaseReactive oxygen species level
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177806
07AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs decreased the inflammatory cytokine TNF-α.
In plain wordsIn mice with colitis, the nanoparticles lowered the inflammatory signal TNF-α.
Peptide
KPV
Outcome
DecreaseTNF-α level
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177807
08AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs decreased the inflammatory cytokine IL-1β.
In plain wordsIn mice with colitis, the nanoparticles lowered the inflammatory signal IL-1β.
Peptide
KPV
Outcome
DecreaseIL-1β level
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177808
09AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs decreased the inflammatory cytokine IL-6.
In plain wordsIn mice with colitis, the nanoparticles lowered the inflammatory signal IL-6.
Peptide
KPV
Outcome
DecreaseIL-6 level
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
After administering with NPs, mice with DSS-induced acute or chronic colitis exhibited significant improvement in body weight, colon length, and disease activity index, decreased the level of the factors associated with oxidative stress (MPO, NO and ROS) and the inflammatory cytokines (TNF-α, IL-1β and IL-6), which implied that NPs could ameliorate murine colitis effectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177809
10AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs notably reduced expression of the macrophage marker CD68.
In plain wordsIn mice with colitis, the nanoparticles reduced a marker of immune macrophage cells in the gut.
Peptide
KPV
Outcome
DecreaseCD68 expression
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
treating by NPs revealed a notable reduction of the expressions of CD68 and CD3
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177810
11AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs notably reduced expression of the T-cell marker CD3.
In plain wordsIn mice with colitis, the nanoparticles reduced a marker of T cells in the gut.
Peptide
KPV
Outcome
DecreaseCD3 expression
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
treating by NPs revealed a notable reduction of the expressions of CD68 and CD3
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177811
12AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs restored Claudin-5 expression, surpassing the KPV and FK506 groups.
In plain wordsIn mice with colitis, the nanoparticles restored a gut-barrier protein more than KPV alone or FK506 alone.
Peptide
KPV
Outcome
IncreaseClaudin-5 expression
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Comparator
KPV group and FK506 group
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
restoring the expression levels of tight junction proteins (Claudin-5, Occludin-1, and ZO-1) were significantly restored, surpassing those observed in the KPV and FK506 groups
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177812
13AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs restored Occludin-1 expression, surpassing the KPV and FK506 groups.
In plain wordsIn mice with colitis, the nanoparticles restored a second gut-barrier protein more than KPV alone or FK506 alone.
Peptide
KPV
Outcome
IncreaseOccludin-1 expression
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Comparator
KPV group and FK506 group
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
restoring the expression levels of tight junction proteins (Claudin-5, Occludin-1, and ZO-1) were significantly restored, surpassing those observed in the KPV and FK506 groups
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177813
14AnimalNot a test of KPV aloneAnimal study (in vivo)Efficacy outcome
In mice with DSS-induced colitis, NPs restored ZO-1 expression, surpassing the KPV and FK506 groups.
In plain wordsIn mice with colitis, the nanoparticles restored a third gut-barrier protein more than KPV alone or FK506 alone.
Peptide
KPV
Outcome
IncreaseZO-1 expression
Study
mousen: not reported in source
DSS-induced acute or chronic colitis
Comparator
KPV group and FK506 group
Outcome group
Gastrointestinal protection · Gastrointestinal
Source sentences
Summary
restoring the expression levels of tight junction proteins (Claudin-5, Occludin-1, and ZO-1) were significantly restored, surpassing those observed in the KPV and FK506 groups
1 context sentence(design, population, supporting numbers)
Summary · context
Five groups of mice were utilized: control that received saline, DSS group (mice received 2.5% DSS or 4% DSS), KPV group (mice received KPV), FK506 group (mice received FK506) and NPs groups (mice received NPs).
In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.
Show in the study text Report a problemFND-3921177814

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 02:56 UTC
First added · source update from Europe PMC

PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.

Summary

Results from this study14

Studies that did not test the peptide alone14

Version history

Subjects

Publication types

Keywords